Clinical trials: HBP
Hypertension
TARGET BP I Clinical Trial
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group…
- Trial name
- TARGET BP I (NCT02910414)
- Testing
- Dehydrated alcohol
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ablative Solutions, Inc.
Glaucoma, Primary Open Angle
Safety and Feasibility of the ELIOS System in POAG Patients
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)
- Trial name
- NCT05999006
- Testing
- ELIOS Procedure
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Elios Vision, Inc.
Glaucoma, Glaucoma, Open Angle
SOLX Titanium Sapphire Laser for Trabeculoplasty
Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure in patients with poorly controlled intraocular pressure on maximally tolerated medical therapy or prior failed laser trabeculoplasty.
- Trial name
- NCT00145535
- Testing
- SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 120 people
- Sponsor
- SOLX, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
- Trial name
- NCT05022004
- Testing
- Brinzolamide ophthalmic suspension, Azopt®
- Where
- 40 sites in India, Russia
- Volunteers
- 599 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Hypertension
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
- Trial name
- NCT00522925
- Testing
- PS433540
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Ligand Pharmaceuticals
Essential Hypertension, Atherosclerotic Cardiovascular Disease
Olmesartan Medoxomil in Atherosclerosis
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
- Trial name
- NCT00185185
- Testing
- Olmesartan medoxomil, Atenolol, Hydrochlorothiazide
- Where
- Germany
- Volunteers
- 165 people
- Sponsor
- Sankyo Pharma Gmbh
Glaucoma
Use of an Ocular Telemetry Sensor in Tafluprost Treated Patients
This clinical trial is designed to investigate the performance of SENSIMED Triggerfish® during 24-hour continuous IOP fluctuation monitoring, defined as the number of valid recording intervals over the 24-hour period.
- Trial name
- NCT01263535
- Testing
- SENSIMED Triggerfish
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Sensimed AG
Hypertension
Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function
This is a Phase 1, open-label, parallel-group study in subjects with varying degrees of renal function to assess the safety, tolerability, and Pharmacokinetics of a single 10 mg oral dose of CIN-107.
- Trial name
- NCT05470725
- Testing
- CIN-107
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension With Dyslipidemia
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
- Trial name
- NCT03247140
- Testing
- JLP-1401, Telmisartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma
PRESERFLO® MicroShunt Extension Study
This prospective, concurrent controlled, open-label, multicenter study is designed to collect additional safety data through 5 years of follow-up for subjects randomized to either the treatment arm (PRESERFLO® MicroShunt with…
- Trial name
- NCT04333433
- Testing
- PRESERFLO® MicroShunt, Trabeculectomy
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 279 people
- Sponsor
- InnFocus Inc.
Essential Hypertension
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of…
- Trial name
- NCT00415038
- Testing
- Rostafuroxin
- Where
- Belgium
- Volunteers
- 438 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Medication Adherence, Hypertension
An Enhanced Medication Monitoring Program
The goal of the Enhanced Medication Management Program (eMMp) being developed by MedMinder Systems, Inc. is to increase the ability of frail elders to adhere to complex medication regimens for chronic conditions.
- Trial name
- NCT01105104
- Testing
- MedMinder System, MedMinder System - deactivated
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- MedMinder Systems Inc.
Hypertension
Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension
The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.
- Trial name
- NASAA (NCT00999752)
- Testing
- Nebivolol, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InVasc Therapeutics, Inc.
Hypertension
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension.
- Trial name
- NCT00523744
- Testing
- Amlodipine, Olmesartan medoxomil, Amlodipine+valsartan
- Where
- 2 sites in Germany
- Volunteers
- 257 people
- Sponsor
- Novartis
Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative
Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.
The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative, Cataract Unilateral Pending Extraction
- Trial name
- Hydrus II (NCT01818115)
- Testing
- Hydrus Implant, IOL placement
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Ivantis, Inc.
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.
- Trial name
- NCT06282549
- Testing
- Telmisartan/Amlodipine/Chlorthalidone(Truset)
- Where
- 5 sites in South Korea
- Volunteers
- 1,219 people
- Sponsor
- Yuhan Corporation
Hypertension
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults
The objective was to evaluate and compare the pharmacokinetic profiles and safety after administration of test drug (CKD-341) and reference drugs (D956) in healthy adults.
- Trial name
- NCT06281132
- Testing
- CKD-341, D956
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
To verify the safety and effectiveness of the renal artery radiofrequency ablation system under the guidance of the three-dimensional cardiac electrophysiological mapping system in the renal denervation of essential hypertension.
- Trial name
- NCT05590871
- Testing
- FlashPoint renal denervation system
- Where
- 27 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Hongdian Medical CO., LTD
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the…
- Trial name
- A DUE (NCT03904693)
- Testing
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 187 people
- Sponsor
- Actelion
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.